Evaluation of an Oral TLR7 Agonist as Part of a Combination HIV Cure Strategy
Time: 1:30 pm
day: Conference Day 2
Details:
- Vesatolimod (VES), an oral, selective TLR7 agonist
- TLR7 activation contributes to remission and/or cure in preclinical models for HIV
- Clinical development of VES for HIV cure
